Business Description
Verrica Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US92511W2070
Total Employee Number:
76Description
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 14.29 | |||||
Equity-to-Asset | 0.41 | |||||
Debt-to-Equity | 0.09 | |||||
Debt-to-EBITDA | -0.13 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | -8.62 | |||||
Beneish M-Score | 3.42 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 8.1 | |||||
3-Year EBITDA Growth Rate | 48.2 | |||||
3-Year EPS without NRI Growth Rate | 37.6 | |||||
3-Year FCF Growth Rate | 33.2 | |||||
3-Year Book Growth Rate | -47.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 45.72 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 35.14 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 49.42 | |||||
9-Day RSI | 51.91 | |||||
14-Day RSI | 51.68 | |||||
3-1 Month Momentum % | 12.52 | |||||
6-1 Month Momentum % | -27.63 | |||||
12-1 Month Momentum % | -34.1 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.1 | |||||
Quick Ratio | 1.98 | |||||
Cash Ratio | 1.27 | |||||
Days Inventory | 215.55 | |||||
Days Sales Outstanding | 68.42 | |||||
Days Payable | 180.28 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -61.1 | |||||
Shareholder Yield % | 23.06 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 89.52 | |||||
Operating Margin % | -36.39 | |||||
Net Margin % | -47.97 | |||||
EBITDA Margin % | -30.57 | |||||
FCF Margin % | -37.98 | |||||
OCF Margin % | -37.98 | |||||
ROA % | -42.83 | |||||
ROIC % | -56.41 | |||||
3-Year ROIIC % | 118.76 | |||||
ROC (Joel Greenblatt) % | -625.49 | |||||
ROCE % | -68.97 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 1.81 | |||||
PB Ratio | 6.66 | |||||
Price-to-Tangible-Book | 6.66 | |||||
EV-to-EBIT | -7.29 | |||||
EV-to-EBITDA | -7.78 | |||||
EV-to-Revenue | 2.38 | |||||
EV-to-Forward-Revenue | 3.59 | |||||
EV-to-FCF | -6.26 | |||||
Price-to-GF-Value | 0.43 | |||||
| Price-to-Net-Current-Asset-Value | 9.48 | |||||
Earnings Yield (Greenblatt) % | -13.72 | |||||
FCF Yield % | -13.12 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VRCA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Verrica Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 37.161 | ||
| EPS (TTM) ($) | -1.03 | ||
| Beta | 1.6277 | ||
| 3-Year Sharpe Ratio | -0.13 | ||
| 3-Year Sortino Ratio | -0.26 | ||
| Volatility % | 164.17 | ||
| 14-Day RSI | 51.68 | ||
| 14-Day ATR ($) | 0.524477 | ||
| 20-Day SMA ($) | 6.076 | ||
| 12-1 Month Momentum % | -34.1 | ||
| 52-Week Range ($) | 3.28 - 9.8212 | ||
| Shares Outstanding (Mil) | 17.18 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Verrica Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Verrica Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-17 08:30 | In 130 days | ||
| Third quarter earnings results for 2026 | 2026-11-17 | In 129 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-12 16:30 | In 33 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 32 days | ||
| General meeting for 2026 | 2026-06-05 10:00 | 6.15 (+4.41%) | ||
| Jefferies Global Healthcare Conference | 2026-06-04 11:05 | 5.87 (+0.34%) | ||
| H.C. Wainwright 4th Annual BioConnect Investor Conference | 2026-05-19 13:30 | 5.87 (-6.38%) | ||
| First quarter earnings conference call for 2026 | 2026-05-12 16:30 | 7.40 (-5.73%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 7.40 (-5.73%) | ||
| 25th Annual Needham Virtual Healthcare Conference | 2026-04-15 15:00 | 5.72 (+0.35%) |
Show
Entries
Verrica Pharmaceuticals Inc Frequently Asked Questions
What is Verrica Pharmaceuticals Inc(VRCA)'s stock price today?
The current price of VRCA is $6.26. The 52 week high of VRCA is $9.82 and 52 week low is $3.28.
When is next earnings date of Verrica Pharmaceuticals Inc(VRCA)?
The next earnings date of Verrica Pharmaceuticals Inc(VRCA) is 2026-08-12 Est..
Does Verrica Pharmaceuticals Inc(VRCA) pay dividends? If so, how much?
Verrica Pharmaceuticals Inc(VRCA) does not pay dividend.
Guru Commentaries on NAS:VRCA
No articles.
Press Release
Articles on Verrica Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers